Teva settles patent case with Perrigo; FDA gives cans and can'ts on cannabis;

@FiercePharma: Which pharma CEOs netted the biggest paychecks of 2013? Find out here. Story | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. Report | Follow @EricPFierce

@CarlyHFierce: Top-read on FierceVaccines Thurs: Merck, Sanofi JV wins anal cancer indication for Gardasil in EU. Article | Follow @CarlyHFierce

> Merck ($MRK), has begun its tender offer for outstanding shares of Idenix ($IDIX), which it is buying for $3.85 billion to boost its portfolio of hepatitis C drugs. Story

> Teva Pharmaceutical Industries ($TEVA) says it has settled patent litigation with Perrigo Pharmaceutical ($PRGO) and Catalent Pharma Solutions, allowing them to sell limited amounts of Perrigo's generic of Teva's ProAir HFA albuterol sulfate inhaler product from Dec. 19, 2016 to June 2018, when the limits will no longer apply. Release

> Peter George, CEO of specialty pharma company Clinigen Group, was named Executive of the Year Award at the 2014 European Mediscience Awards. Release

> The FDA says it is now using some cloud computing so that it can work with big data files. Blog

Medical Device News

@FierceMedDev: Covidien endovascular unit could be target for cuts after Medtronic merger. More | Follow @FierceMedDev

@StacyALawrence: How clinically useful is genome sequencing? Not very, yet. Story | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: "Smartcane" device uses bat-inspired sonar technology to improve independent mobility in the blind. Article | Follow @EmilyWFierce

> Medtronic's tax inversion scheme won't be all fun and games, experts say. More

> Danaher is a big question mark looming amid med tech M&A frenzy. Story

> Med tech outfits head to market with newly planned IPOs. Article

Biotech News

@FierceBiotech: Bristol-Myers toes the next hep C frontier: a four-week cure. Story | Follow @FierceBiotech

@JohnCFierce: Man, that Burrill lawsuit makes for interesting reading. More | Follow @JohnCFierce

@DamianFierce: BIO2014 prediction: After a hall-of-fame career, "robust" classily gives way to promising rookie "disruptive." | Follow @DamianFierce

> Kite Pharma rides the CAR-T current to a $128M IPO. Story

> AbbVie and Shire square off over a spurned $46B buyout offer. More

> After three strikes, Sanofi gives up on Merrimack's cancer drug. News

And Finally... The FDA has outlined the measures required to use marijuana in clinical trials. More

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.